| Particulars (Rupees in Crores.) | Mar-2025 | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 |
|---|---|---|---|---|---|
Gross Sales | 3,729.5 | 3,462.6 | 3,411.6 | 3,233.2 | 3,194.1 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 3,729.5 | 3,462.6 | 3,411.6 | 3,233.2 | 3,194.1 |
Other Operating Income | 21 | 21.4 | 24.1 | 34 | 36.4 |
Other Income | -1.1 | 417.4 | 66.7 | 26.1 | 26.2 |
Total Income | 3,749.4 | 3,901.4 | 3,502.4 | 3,293.3 | 3,256.7 |
Total Expenditure | 3,118.1 | 2,943.2 | 3,115.2 | 2,855.8 | 2,862.6 |
PBIDT | 631.3 | 958.2 | 387.2 | 437.5 | 394.1 |
Interest | 108.3 | 132 | 144.3 | 128 | 106.3 |
PBDT | 523 | 826.2 | 242.9 | 309.5 | 287.8 |
Depreciation | 186.5 | 182.1 | 195.6 | 186.3 | 365.5 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 147.1 | 66.1 | 153.2 | 49.4 | 49.6 |
Deferred Tax | -62.6 | -6.3 | -110.5 | 5.7 | -10.7 |
Reported Profit After Tax | 252 | 584.3 | 4.6 | 68.1 | -116.6 |
Minority Interest After NP | -2.5 | -0.6 | -3.6 | -0.8 | -3.1 |
Net Profit after Minority Interest | 254.5 | 584.9 | 8.2 | 68.9 | -113.5 |
Extra-ordinary Items | -22.2 | 342.53 | -168.9 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 276.7 | 242.37 | 177.1 | 68.9 | -113.5 |
EPS (Unit Curr.) | 16.11 | 36.91 | 0.52 | 4.34 | 0 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 15.8 | 15.8 | 15.8 | 15.8 | 15.9 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 16.92 | 27.67 | 11.34 | 13.53 | 12.33 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 6.75 | 16.87 | 0.13 | 2.1 | -3.65 |
The API division posted a turnover of ₹609 Crore for the financial year ended March 2025. This was 8.35% of the company’s consolidated revenue.
Here are some of the stocks that may see significant price movement today: Torrent Power, DCM Shriram, Jubilant Pharmova, etc.
This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.
Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
